XML 69 R51.htm IDEA: XBRL DOCUMENT
v3.22.1

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Apr. 03, 2022 | Apr. 04, 2021
Sales by segment of business |  |
Sales to customers | $ 23,426 | $ 22,321
Percent Change (as a percent) | 5.00% |
U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 11,414 | 11,111
Percent Change (as a percent) | 2.70% |
International |  |
Sales by segment of business |  |
Sales to customers | $ 12,012 | 11,210
Percent Change (as a percent) | 7.20% |
CONSUMER HEALTH |  |
Sales by segment of business |  |
Sales to customers | $ 3,586 | 3,641
Percent Change (as a percent) | (1.50%) |
CONSUMER HEALTH | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,557 | 1,611
Percent Change (as a percent) | (3.40%) |
CONSUMER HEALTH | International |  |
Sales by segment of business |  |
Sales to customers | $ 2,029 | 2,030
Percent Change (as a percent) | 0.00% |
CONSUMER HEALTH | OTC [Member] |  |
Sales by segment of business |  |
Sales to customers | $ 1,461 | 1,273
Percent Change (as a percent) | 14.80% |
CONSUMER HEALTH | OTC [Member] | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 670 | 599
Percent Change (as a percent) | 11.80% |
CONSUMER HEALTH | OTC [Member] | International |  |
Sales by segment of business |  |
Sales to customers | $ 791 | 673
Percent Change (as a percent) | 17.50% |
CONSUMER HEALTH | Skin Health/Beauty |  |
Sales by segment of business |  |
Sales to customers | $ 1,012 | 1,163
Percent Change (as a percent) | (13.00%) |
CONSUMER HEALTH | Skin Health/Beauty | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 544 | 634
Percent Change (as a percent) | (14.20%) |
CONSUMER HEALTH | Skin Health/Beauty | International |  |
Sales by segment of business |  |
Sales to customers | $ 468 | 529
Percent Change (as a percent) | (11.60%) |
CONSUMER HEALTH | Oral Care |  |
Sales by segment of business |  |
Sales to customers | $ 366 | 417
Percent Change (as a percent) | (12.20%) |
CONSUMER HEALTH | Oral Care | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 143 | 163
Percent Change (as a percent) | (12.60%) |
CONSUMER HEALTH | Oral Care | International |  |
Sales by segment of business |  |
Sales to customers | $ 223 | 254
Percent Change (as a percent) | (12.00%) |
CONSUMER HEALTH | Baby Care |  |
Sales by segment of business |  |
Sales to customers | $ 355 | 389
Percent Change (as a percent) | (8.60%) |
CONSUMER HEALTH | Baby Care | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 85 | 96
Percent Change (as a percent) | (11.50%) |
CONSUMER HEALTH | Baby Care | International |  |
Sales by segment of business |  |
Sales to customers | $ 270 | 293
Percent Change (as a percent) | (7.70%) |
CONSUMER HEALTH | Women's Health |  |
Sales by segment of business |  |
Sales to customers | $ 228 | 222
Percent Change (as a percent) | 2.60% |
CONSUMER HEALTH | Women's Health | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 3 | 3
Percent Change (as a percent) | 7.20% |
CONSUMER HEALTH | Women's Health | International |  |
Sales by segment of business |  |
Sales to customers | $ 224 | 219
Percent Change (as a percent) | 2.50% |
CONSUMER HEALTH | Wound Care/Other |  |
Sales by segment of business |  |
Sales to customers | $ 164 | 177
Percent Change (as a percent) | (7.40%) |
CONSUMER HEALTH | Wound Care/Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 112 | 115
Percent Change (as a percent) | (3.30%) |
CONSUMER HEALTH | Wound Care/Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 52 | 61
Percent Change (as a percent) | (15.30%) |
PHARMACEUTICAL |  |
Sales by segment of business |  |
Sales to customers | $ 12,869 | 12,101
Percent Change (as a percent) | 6.30% |
PHARMACEUTICAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 6,632 | 6,446
Percent Change (as a percent) | 2.90% |
PHARMACEUTICAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 6,237 | 5,655
Percent Change (as a percent) | 10.30% |
PHARMACEUTICAL | Immunology |  |
Sales by segment of business |  |
Sales to customers | $ 4,119 | 3,914
Percent Change (as a percent) | 5.20% |
PHARMACEUTICAL | Immunology | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 2,501 | 2,413
Percent Change (as a percent) | 3.70% |
PHARMACEUTICAL | Immunology | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,617 | 1,501
Percent Change (as a percent) | 7.70% |
PHARMACEUTICAL | Immunology | REMICADE |  |
Sales by segment of business |  |
Sales to customers | $ 663 | 777
Percent Change (as a percent) | (14.70%) |
PHARMACEUTICAL | Immunology | REMICADE | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 358 | 489
Percent Change (as a percent) | (26.80%) |
PHARMACEUTICAL | Immunology | REMICADE | U.S. Exports |  |
Sales by segment of business |  |
Sales to customers | $ 80 | 57
Percent Change (as a percent) | 40.50% |
PHARMACEUTICAL | Immunology | REMICADE | International |  |
Sales by segment of business |  |
Sales to customers | $ 225 | 232
Percent Change (as a percent) | (2.60%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA |  |
Sales by segment of business |  |
Sales to customers | $ 571 | 562
Percent Change (as a percent) | 1.50% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 287 | 255
Percent Change (as a percent) | 12.50% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA | International |  |
Sales by segment of business |  |
Sales to customers | $ 283 | 307
Percent Change (as a percent) | (7.60%) |
PHARMACEUTICAL | Immunology | STELARA |  |
Sales by segment of business |  |
Sales to customers | $ 2,288 | 2,148
Percent Change (as a percent) | 6.50% |
PHARMACEUTICAL | Immunology | STELARA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,379 | 1,331
Percent Change (as a percent) | 3.60% |
PHARMACEUTICAL | Immunology | STELARA | International |  |
Sales by segment of business |  |
Sales to customers | $ 909 | 817
Percent Change (as a percent) | 11.20% |
PHARMACEUTICAL | Immunology | TREMFYA |  |
Sales by segment of business |  |
Sales to customers | $ 590 | 418
Percent Change (as a percent) | 41.30% |
PHARMACEUTICAL | Immunology | TREMFYA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 391 | 274
Percent Change (as a percent) | 42.70% |
PHARMACEUTICAL | Immunology | TREMFYA | International |  |
Sales by segment of business |  |
Sales to customers | $ 199 | 143
Percent Change (as a percent) | 38.80% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY |  |
Sales by segment of business |  |
Sales to customers | $ 6 | 8
Percent Change (as a percent) | (22.00%) |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 6 | 7
Percent Change (as a percent) | (3.20%) |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International |  |
Sales by segment of business |  |
Sales to customers | $ 0 | 2
PHARMACEUTICAL | Infectious Diseases |  |
Sales by segment of business |  |
Sales to customers | $ 1,297 | 998
Percent Change (as a percent) | 30.00% |
PHARMACEUTICAL | Infectious Diseases | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 461 | 512
Percent Change (as a percent) | (10.00%) |
PHARMACEUTICAL | Infectious Diseases | International |  |
Sales by segment of business |  |
Sales to customers | $ 836 | 485
Percent Change (as a percent) | 72.30% |
PHARMACEUTICAL | Infectious Diseases | COVID-19 |  |
Sales by segment of business |  |
Sales to customers | $ 457 | 100
PHARMACEUTICAL | Infectious Diseases | COVID-19 | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 75 | 100
Percent Change (as a percent) | (24.90%) |
PHARMACEUTICAL | Infectious Diseases | COVID-19 | International |  |
Sales by segment of business |  |
Sales to customers | $ 382 | 0
PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine |  |
Sales by segment of business |  |
Sales to customers | $ 248 | 243
Percent Change (as a percent) | 1.80% |
PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 9 | 10
Percent Change (as a percent) | (12.60%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine | International |  |
Sales by segment of business |  |
Sales to customers | $ 239 | 233
Percent Change (as a percent) | 2.50% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |
Sales by segment of business |  |
Sales to customers | $ 501 | 546
Percent Change (as a percent) | (8.30%) |
PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 369 | 380
Percent Change (as a percent) | (3.10%) |
PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International |  |
Sales by segment of business |  |
Sales to customers | $ 132 | 166
Percent Change (as a percent) | (20.30%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES( |  |
Sales by segment of business |  |
Sales to customers | $ 91 | 108
Percent Change (as a percent) | (15.30%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES( | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 8 | 21
Percent Change (as a percent) | (62.50%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES( | International |  |
Sales by segment of business |  |
Sales to customers | $ 83 | 87
Percent Change (as a percent) | (3.80%) |
PHARMACEUTICAL | Neuroscience |  |
Sales by segment of business |  |
Sales to customers | $ 1,741 | 1,715
Percent Change (as a percent) | 1.50% |
PHARMACEUTICAL | Neuroscience | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 843 | 771
Percent Change (as a percent) | 9.30% |
PHARMACEUTICAL | Neuroscience | International |  |
Sales by segment of business |  |
Sales to customers | $ 898 | 943
Percent Change (as a percent) | (4.80%) |
PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate |  |
Sales by segment of business |  |
Sales to customers | $ 157 | 171
Percent Change (as a percent) | (8.30%) |
PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 35 | 47
Percent Change (as a percent) | (26.50%) |
PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate | International |  |
Sales by segment of business |  |
Sales to customers | $ 122 | 123
Percent Change (as a percent) | (1.30%) |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |
Sales by segment of business |  |
Sales to customers | $ 1,048 | 965
Percent Change (as a percent) | 8.60% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 661 | 589
Percent Change (as a percent) | 12.20% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International |  |
Sales by segment of business |  |
Sales to customers | $ 387 | 376
Percent Change (as a percent) | 3.00% |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA |  |
Sales by segment of business |  |
Sales to customers | $ 129 | 157
Percent Change (as a percent) | (17.60%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 63 | 67
Percent Change (as a percent) | (6.40%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA | International |  |
Sales by segment of business |  |
Sales to customers | $ 66 | 89
Percent Change (as a percent) | (26.10%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE |  |
Sales by segment of business |  |
Sales to customers | $ 408 | 422
Percent Change (as a percent) | (3.50%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 84 | 67
Percent Change (as a percent) | 25.50% |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International |  |
Sales by segment of business |  |
Sales to customers | $ 323 | 355
Percent Change (as a percent) | (8.90%) |
PHARMACEUTICAL | Oncology |  |
Sales by segment of business |  |
Sales to customers | $ 3,950 | 3,570
Percent Change (as a percent) | 10.60% |
PHARMACEUTICAL | Oncology | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,582 | 1,377
Percent Change (as a percent) | 14.90% |
PHARMACEUTICAL | Oncology | International |  |
Sales by segment of business |  |
Sales to customers | $ 2,369 | 2,193
Percent Change (as a percent) | 8.00% |
PHARMACEUTICAL | Oncology | DARZALEX |  |
Sales by segment of business |  |
Sales to customers | $ 1,856 | 1,365
Percent Change (as a percent) | 36.00% |
PHARMACEUTICAL | Oncology | DARZALEX | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 953 | 691
Percent Change (as a percent) | 37.90% |
PHARMACEUTICAL | Oncology | DARZALEX | International |  |
Sales by segment of business |  |
Sales to customers | $ 903 | 674
Percent Change (as a percent) | 34.00% |
PHARMACEUTICAL | Oncology | ERLEADA |  |
Sales by segment of business |  |
Sales to customers | $ 400 | 261
Percent Change (as a percent) | 53.00% |
PHARMACEUTICAL | Oncology | ERLEADA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 206 | 171
Percent Change (as a percent) | 20.30% |
PHARMACEUTICAL | Oncology | ERLEADA | International |  |
Sales by segment of business |  |
Sales to customers | $ 194 | 90
PHARMACEUTICAL | Oncology | IMBRUVICA |  |
Sales by segment of business |  |
Sales to customers | $ 1,038 | 1,125
Percent Change (as a percent) | (7.70%) |
PHARMACEUTICAL | Oncology | IMBRUVICA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 370 | 444
Percent Change (as a percent) | (16.70%) |
PHARMACEUTICAL | Oncology | IMBRUVICA | International |  |
Sales by segment of business |  |
Sales to customers | $ 668 | 680
Percent Change (as a percent) | (1.80%) |
PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate |  |
Sales by segment of business |  |
Sales to customers | $ 539 | 638
Percent Change (as a percent) | (15.60%) |
PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 19 | 50
Percent Change (as a percent) | (62.10%) |
PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate | International |  |
Sales by segment of business |  |
Sales to customers | $ 520 | 588
Percent Change (as a percent) | (11.60%) |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY |  |
Sales by segment of business |  |
Sales to customers | $ 118 | 182
Percent Change (as a percent) | (35.10%) |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 34 | 21
Percent Change (as a percent) | 63.10% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International |  |
Sales by segment of business |  |
Sales to customers | $ 84 | 161
Percent Change (as a percent) | (47.70%) |
PHARMACEUTICAL | Pulmonary Hypertension |  |
Sales by segment of business |  |
Sales to customers | $ 852 | 861
Percent Change (as a percent) | (1.10%) |
PHARMACEUTICAL | Pulmonary Hypertension | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 572 | 573
Percent Change (as a percent) | (0.20%) |
PHARMACEUTICAL | Pulmonary Hypertension | International |  |
Sales by segment of business |  |
Sales to customers | $ 279 | 288
Percent Change (as a percent) | (2.90%) |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT |  |
Sales by segment of business |  |
Sales to customers | $ 443 | 450
Percent Change (as a percent) | (1.60%) |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 273 | 272
Percent Change (as a percent) | 0.50% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT | International |  |
Sales by segment of business |  |
Sales to customers | $ 170 | 179
Percent Change (as a percent) | (4.80%) |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI |  |
Sales by segment of business |  |
Sales to customers | $ 325 | 305
Percent Change (as a percent) | 6.50% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 269 | 259
Percent Change (as a percent) | 3.90% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI | International |  |
Sales by segment of business |  |
Sales to customers | $ 56 | 46
Percent Change (as a percent) | 20.90% |
PHARMACEUTICAL | Pulmonary Hypertension | Other |  |
Sales by segment of business |  |
Sales to customers | $ 83 | 105
Percent Change (as a percent) | (20.80%) |
PHARMACEUTICAL | Pulmonary Hypertension | Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 30 | 42
Percent Change (as a percent) | (29.00%) |
PHARMACEUTICAL | Pulmonary Hypertension | Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 53 | 63
Percent Change (as a percent) | (15.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other |  |
Sales by segment of business |  |
Sales to customers | $ 910 | 1,044
Percent Change (as a percent) | (12.80%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 672 | 799
Percent Change (as a percent) | (15.80%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 238 | 245
Percent Change (as a percent) | (3.00%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO |  |
Sales by segment of business |  |
Sales to customers | $ 508 | 589
Percent Change (as a percent) | (13.80%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 508 | 589
Percent Change (as a percent) | (13.80%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO | International |  |
Sales by segment of business |  |
Sales to customers | $ 0 | 0
Percent Change (as a percent) | 0.00% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET |  |
Sales by segment of business |  |
Sales to customers | $ 128 | 150
Percent Change (as a percent) | (14.60%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 60 | 87
Percent Change (as a percent) | (30.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | International |  |
Sales by segment of business |  |
Sales to customers | $ 68 | 63
Percent Change (as a percent) | 7.50% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other |  |
Sales by segment of business |  |
Sales to customers | $ 274 | 305
Percent Change (as a percent) | (10.00%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 104 | 122
Percent Change (as a percent) | (14.90%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 170 | 182
Percent Change (as a percent) | (6.60%) |
MEDTECH(3) |  |
Sales by segment of business |  |
Sales to customers | $ 6,971 | 6,579
Percent Change (as a percent) | 5.90% |
MEDTECH(3) | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 3,225 | 3,054
Percent Change (as a percent) | 5.60% |
MEDTECH(3) | International |  |
Sales by segment of business |  |
Sales to customers | $ 3,746 | 3,525
Percent Change (as a percent) | 6.30% |
MEDTECH(3) | Interventional Solutions |  |
Sales by segment of business |  |
Sales to customers | $ 1,092 | 949
Percent Change (as a percent) | 15.10% |
MEDTECH(3) | Interventional Solutions | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 494 | 434
Percent Change (as a percent) | 13.80% |
MEDTECH(3) | Interventional Solutions | International |  |
Sales by segment of business |  |
Sales to customers | $ 597 | 514
Percent Change (as a percent) | 16.20% |
MEDTECH(3) | Orthopaedics |  |
Sales by segment of business |  |
Sales to customers | $ 2,188 | 2,113
Percent Change (as a percent) | 3.50% |
MEDTECH(3) | Orthopaedics | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,289 | 1,249
Percent Change (as a percent) | 3.20% |
MEDTECH(3) | Orthopaedics | International |  |
Sales by segment of business |  |
Sales to customers | $ 899 | 864
Percent Change (as a percent) | 4.10% |
MEDTECH(3) | Orthopaedics | HIPS |  |
Sales by segment of business |  |
Sales to customers | $ 389 | 356
Percent Change (as a percent) | 9.30% |
MEDTECH(3) | Orthopaedics | HIPS | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 225 | 209
Percent Change (as a percent) | 7.30% |
MEDTECH(3) | Orthopaedics | HIPS | International |  |
Sales by segment of business |  |
Sales to customers | $ 164 | 146
Percent Change (as a percent) | 12.20% |
MEDTECH(3) | Orthopaedics | KNEES |  |
Sales by segment of business |  |
Sales to customers | $ 339 | 317
Percent Change (as a percent) | 6.70% |
MEDTECH(3) | Orthopaedics | KNEES | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 201 | 185
Percent Change (as a percent) | 8.60% |
MEDTECH(3) | Orthopaedics | KNEES | International |  |
Sales by segment of business |  |
Sales to customers | $ 138 | 132
Percent Change (as a percent) | 4.10% |
MEDTECH(3) | Orthopaedics | TRAUMA |  |
Sales by segment of business |  |
Sales to customers | $ 748 | 733
Percent Change (as a percent) | 2.10% |
MEDTECH(3) | Orthopaedics | TRAUMA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 475 | 450
Percent Change (as a percent) | 5.50% |
MEDTECH(3) | Orthopaedics | TRAUMA | International |  |
Sales by segment of business |  |
Sales to customers | $ 273 | 282
Percent Change (as a percent) | (3.30%) |
MEDTECH(3) | Orthopaedics | SPINE, SPORTS & OTHER |  |
Sales by segment of business |  |
Sales to customers | $ 712 | 707
Percent Change (as a percent) | 0.60% |
MEDTECH(3) | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 387 | 404
Percent Change (as a percent) | (4.10%) |
MEDTECH(3) | Orthopaedics | SPINE, SPORTS & OTHER | International |  |
Sales by segment of business |  |
Sales to customers | $ 324 | 303
Percent Change (as a percent) | 7.00% |
MEDTECH(3) | Surgery |  |
Sales by segment of business |  |
Sales to customers | $ 2,434 | 2,372
Percent Change (as a percent) | 2.60% |
MEDTECH(3) | Surgery | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 921 | 898
Percent Change (as a percent) | 2.50% |
MEDTECH(3) | Surgery | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,513 | 1,474
Percent Change (as a percent) | 2.70% |
MEDTECH(3) | Surgery | ADVANCED |  |
Sales by segment of business |  |
Sales to customers | $ 1,146 | 1,118
Percent Change (as a percent) | 2.50% |
MEDTECH(3) | Surgery | ADVANCED | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 417 | 405
Percent Change (as a percent) | 3.00% |
MEDTECH(3) | Surgery | ADVANCED | International |  |
Sales by segment of business |  |
Sales to customers | $ 729 | 713
Percent Change (as a percent) | 2.20% |
MEDTECH(3) | Surgery | GENERAL |  |
Sales by segment of business |  |
Sales to customers | $ 1,288 | 1,254
Percent Change (as a percent) | 2.70% |
MEDTECH(3) | Surgery | GENERAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 504 | 493
Percent Change (as a percent) | 2.10% |
MEDTECH(3) | Surgery | GENERAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 784 | 761
Percent Change (as a percent) | 3.10% |
MEDTECH(3) | Vision |  |
Sales by segment of business |  |
Sales to customers | $ 1,257 | 1,145
Percent Change (as a percent) | 9.80% |
MEDTECH(3) | Vision | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 521 | 472
Percent Change (as a percent) | 10.40% |
MEDTECH(3) | Vision | International |  |
Sales by segment of business |  |
Sales to customers | $ 736 | 673
Percent Change (as a percent) | 9.40% |
MEDTECH(3) | Vision | CONTACT LENSES / OTHER |  |
Sales by segment of business |  |
Sales to customers | $ 910 | 857
Percent Change (as a percent) | 6.20% |
MEDTECH(3) | Vision | CONTACT LENSES / OTHER | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 400 | 371
Percent Change (as a percent) | 7.70% |
MEDTECH(3) | Vision | CONTACT LENSES / OTHER | International |  |
Sales by segment of business |  |
Sales to customers | $ 511 | 486
Percent Change (as a percent) | 5.10% |
MEDTECH(3) | Vision | SURGICAL |  |
Sales by segment of business |  |
Sales to customers | $ 347 | 288
Percent Change (as a percent) | 20.40% |
MEDTECH(3) | Vision | SURGICAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 121 | 101
Percent Change (as a percent) | 20.20% |
MEDTECH(3) | Vision | SURGICAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 226 | 187
Percent Change (as a percent) | 20.50% |
CONSUMER HEALTH and PHARMACEUTICAL [Member] | OTC [Member] | CHINA |  |
Sales by segment of business |  |
Sales to customers |  | $ 100

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ERLEADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |